tecentriq
roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agentes antineoplásicos - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
tecentriq recombinante concentrado para solución para perfusión 1200 mg/20 ml (atezolizumab)
roche chile ltda. - atezolizumab - sin formulas
tecentriq (atezolizumab) 60 mg / ml concentrado para solucion para infusion
productos roche, s.a. - atezolizumab - concentrado para solucion para infusion - 60 mg / ml
tecentriq
f. hoffmann-la roche s.a, basilea, suiza. - atezolizumab -
tecentriq 1200 mg/20ml concentrado para solución para perfusión
atezolizumab - concentrado para solución para perfusión - 1200 mg/20ml
tecentriq®
roche diagnostics gmbh - atezolizumab - concentrado para solución para infusión, iv. - 60 mg/ml
tecentriq concentrado para solución para perfusión 1200 mg/20 ml
roche chile ltda. - atezolizumab - sin formulas
tecentriq concentrado para solución para perfusión 840 mg /14 ml
roche chile ltda. - atezolizumab - sin formulas
tecentriq 1200 mg/ 20 ml concentrado para solucion para perfusion
roche farma (peru) s.a. - droguerÍa - atezolizumab - concentrado para solucion para perfusion - 1200 mg/20 ml - por vial 20.00 mg - - agentes antineoplÁsicos
tecentriq 1200 mg/ 20 ml concentrado para solucion para perfusion
roche farma (peru) s.a. - droguerÍa - atezolizumab - concentrado para solucion para perfusion - 1200 mg/20ml - por dosis 20.00 ml - - agentes antineoplÁsicos